Hub : Traits :

Qualifications: A levels/AS levels or equivalent

460 significantly associated models · 88 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 41130424 42542658 1 1 2.3e-07 3.0e-07 9.4e-04 58 FOXO6
2 1 43152610 45153116 10 4 3.1e-12 3.9e-13 8.2e-01 100 ARTN MED8 ST3GAL3
3 1 71163715 73435171 1 1 8.2e-08 1.8e-08 1.8e-06 28 NEGR1
4 2 43899918 45698128 1 1 3.0e-08 5.4e-10 5.0e-03 80 CAMKMT
5 2 100193898 101731705 2 1 6.0e-10 2.4e-10 1.0e+00 100 LONRF2
6 2 156594333 158165818 1 1 8.3e-09 5.1e-09 3.2e-03 74 GPD2
7 2 161297929 162790882 1 1 4.0e-08 5.3e-10 1.5e-03 74 TANK
8 3 48029118 51043528 29 7 3.9e-26 1.4e-23 1.0e+00 100 APEH IP6K2 MST1R RBM6 RNF123 UBA7
9 3 84767271 86367480 1 1 3.4e-09 2.7e-08 5.6e-03 75 CADM2
10 4 151637154 153275701 1 1 2.4e-07 8.6e-08 1.2e-04 48 FAM160A1
11 5 59353199 61156570 4 1 6.3e-09 5.9e-09 1.6e-01 94 ERCC8
12 7 1161158 2969983 1 1 6.1e-08 1.5e-08 1.0e-02 79 MAD1L1
13 7 23913624 25432157 1 1 9.6e-09 5.5e-09 1.0e+00 100 MPP6
14 7 74339397 75842792 3 1 2.2e-07 4.2e-07 2.1e-01 94 POM121C
15 8 142629143 144515639 2 2 1.7e-08 2.6e-09 4.7e-03 78 THEM6 TSNARE1
16 10 10349662 12076043 1 1 7.6e-08 1.1e-08 7.2e-03 78 CELF2
17 10 64195778 65606229 2 1 1.4e-08 8.9e-09 6.0e-02 89 NRBF2
18 10 103940629 104440050 1 1 1.4e-07 4.9e-09 9.9e-03 81 CUEDC2
19 11 94805896 96276010 4 1 2.9e-13 1.1e-12 3.8e-01 98 AP001877.1
20 12 122713991 124591385 11 1 1.4e-14 7.4e-15 7.7e-02 95 RP11-282O18.3
21 16 9598191 10524165 1 1 1.4e-08 1.3e-10 1.8e-03 76 GRIN2A
22 19 36003721 36487759 1 1 2.9e-07 3.3e-06 3.7e-01 96 LIN37
23 19 45569009 46073472 1 1 3.4e-10 2.1e-08 3.7e-01 98 CKM

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.21 1 0 0.0 0.00 1.0e+00 MPP6
Bipolar Disorder or Schizophrenia 2.14 4 2 4.4 -0.20 8.0e-01 MED8 MPP6 RP11-282O18.3 ST3GAL3
Depressed Affect (Nagel 2018) 4.11 8 4 8.9 -0.98 3.3e-06 APEH CELF2 MST1R RBM6 RNF123 TANK THEM6 UBA7
Intelligence (Savage-Jansen 2018) 13.65 23 15 33.3 0.97 2.1e-16 AP001877.1 APEH ARTN CAMKMT CKM CUEDC2 ERCC8 FAM160A1 FOXO6 LIN37 LONRF2 MED8 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK TSNARE1 UBA7
Neuroticism (Nagel 2018) 2.08 3 0 0.0 0.00 1.0e+00 CELF2 THEM6 TSNARE1
Schizophrenia (2018) 2.85 4 0 0.0 -0.42 5.8e-01 ERCC8 MED8 RP11-282O18.3 ST3GAL3
Worry (Nagel 2018) 1.89 3 0 0.0 0.00 1.0e+00 AP001877.1 CADM2 TSNARE1
Crohns Disease (2017) 5.13 5 5 11.1 0.96 2.4e-03 APEH MST1R RBM6 RNF123 UBA7
Irritable Bowel Disease (IBD) 6.34 5 5 11.1 0.96 2.4e-03 APEH MST1R RBM6 RNF123 UBA7
Ulcerative Colitis (UC) 4.96 5 5 11.1 0.97 1.4e-03 APEH MST1R RBM6 RNF123 UBA7
Major Depression (MDD) 3.33 1 1 2.2 0.00 1.0e+00 NEGR1
Reaction Time 2.11 1 0 0.0 0.00 1.0e+00 RNF123
Verbal and Numeric Reasoning (VNR) 11.11 15 11 24.4 0.97 5.9e-11 APEH ARTN CKM CUEDC2 FAM160A1 FOXO6 LONRF2 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK UBA7
Breast Cancer 1.83 2 0 0.0 0.00 1.0e+00 APEH UBA7
Prostate Cancer 2.24 1 0 0.0 0.00 1.0e+00 UBA7
Age at First Birth 8.93 6 5 11.1 1.00 2.1e-06 APEH LONRF2 MST1R RBM6 RNF123 UBA7
Body Mass Index (BMI) (2010) 3.50 1 1 2.2 0.00 1.0e+00 NEGR1
Coronary Artery Disease (CAD) 2.86 1 0 0.0 0.00 1.0e+00 RBM6
Crohns Disease (2012) 5.14 5 5 11.1 0.98 4.3e-04 APEH MST1R RBM6 RNF123 UBA7
HDL Cholesterol 1.98 2 0 0.0 0.00 1.0e+00 NRBF2 RBM6
Neuroticism (2016) 2.23 1 0 0.0 0.00 1.0e+00 TANK
Schizophrenia (2014) 2.39 3 1 2.2 0.00 1.0e+00 ERCC8 RP11-282O18.3 ST3GAL3
Triglycerides 1.54 1 1 2.2 0.00 1.0e+00 NRBF2
Ulcerative Colitis 4.79 5 4 8.9 0.98 3.1e-03 APEH MST1R RBM6 RNF123 UBA7
Blood Eosinophil Count 1.10 4 3 6.7 -0.85 6.8e-02 CKM RBM6 RP11-282O18.3 UBA7
Blood Platelet Count 4.44 6 4 8.9 0.12 8.2e-01 CKM FAM160A1 MPP6 NRBF2 RP11-282O18.3 ST3GAL3
Blood Red Count 1.45 13 5 11.1 -0.48 1.0e-01 AP001877.1 CAMKMT CKM ERCC8 IP6K2 MED8 MST1R NRBF2 POM121C RBM6 RNF123 ST3GAL3 UBA7
Blood White Count 3.43 11 8 17.8 -0.69 1.3e-02 APEH CKM FAM160A1 FOXO6 MED8 MPP6 MST1R NRBF2 RBM6 RNF123 UBA7
Heel T-Score 2.38 7 6 13.3 -0.90 2.3e-03 APEH MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
BMI 7.79 14 11 24.4 -0.86 4.0e-05 APEH CADM2 CAMKMT IP6K2 LIN37 LONRF2 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 THEM6 UBA7
Height 1.20 12 6 13.3 0.84 6.4e-04 AP001877.1 CAMKMT ERCC8 FAM160A1 MED8 MPP6 MST1R NRBF2 POM121C RNF123 RP11-282O18.3 ST3GAL3
Waist Hip Ratio (WHR) 1.32 2 1 2.2 0.00 1.0e+00 ERCC8 RP11-282O18.3
Systolic Blood Pressure 2.13 7 3 6.7 -0.64 1.2e-01 APEH MED8 MPP6 POM121C RNF123 TSNARE1 UBA7
Smoking Status 4.37 6 5 11.1 -0.98 5.4e-04 CADM2 CELF2 ERCC8 MED8 ST3GAL3 TANK
Allergy or Eczema 1.60 2 0 0.0 0.00 1.0e+00 NEGR1 RP11-282O18.3
Cardiovascular Disease 2.15 4 1 2.2 -0.27 7.3e-01 MED8 NEGR1 RNF123 THEM6
Hypothyroidism (self reported) 1.34 1 1 2.2 0.00 1.0e+00 TANK
Respiratory disease 1.84 1 0 0.0 0.00 1.0e+00 RBM6
Type 2 Diabetes (T2D) (2018) 3.31 4 2 4.4 -0.99 4.3e-04 MST1R RBM6 RNF123 UBA7
Lung FEV1/FVC ratio 1.36 2 2 4.4 0.00 1.0e+00 NEGR1 NRBF2
Lung FVC 1.67 8 2 4.4 0.48 2.3e-01 APEH FOXO6 GPD2 MST1R NRBF2 RBM6 RP11-282O18.3 UBA7
Neuroticism 2.12 3 0 0.0 0.00 1.0e+00 RNF123 TSNARE1 UBA7
Chronotype (morning person) 1.77 1 0 0.0 0.00 1.0e+00 CAMKMT
Hair Pigment 0.12 1 1 2.2 0.00 1.0e+00 RP11-282O18.3
Tanning 0.45 1 0 0.0 0.00 1.0e+00 CADM2
Hand grip strength (left) 1.63 3 0 0.0 0.00 1.0e+00 CADM2 CUEDC2 FAM160A1
Number of treatments/medications taken 5.32 7 4 8.9 -0.87 5.3e-03 APEH MST1R NEGR1 RBM6 RNF123 TANK UBA7
Average weekly spirits intake 2.86 1 0 0.0 0.00 1.0e+00 APEH
Frequency of depressed mood in last 2 weeks 1.90 1 0 0.0 0.00 1.0e+00 CELF2
Relative age of first facial hair 1.75 2 0 0.0 0.00 1.0e+00 MED8 NRBF2
Systolic blood pressure, automated reading 2.66 6 2 4.4 -0.75 8.6e-02 APEH MED8 MPP6 RNF123 TSNARE1 UBA7
Supplements: Zinc 1.92 1 0 0.0 0.00 1.0e+00 NRBF2
Medication: Co-codamol 3.52 4 0 0.0 -1.00 4.1e-06 MST1R RBM6 RNF123 UBA7
Impedance of leg (right) 2.29 9 5 11.1 0.47 1.7e-01 AP001877.1 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 UBA7
Leg fat-free mass (left) 3.36 11 8 17.8 -0.53 7.4e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Trunk fat percentage 5.10 12 8 17.8 -0.89 3.9e-05 APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Hand grip strength (right) 1.88 3 0 0.0 0.00 1.0e+00 CADM2 CUEDC2 FAM160A1
Townsend deprivation index at recruitment 1.97 1 0 0.0 0.00 1.0e+00 CKM
Current tobacco smoking 3.24 1 0 0.0 0.00 1.0e+00 ST3GAL3
Maternal smoking around birth 4.27 3 0 0.0 0.00 1.0e+00 CKM MED8 RNF123
Fed-up feelings 5.24 7 4 8.9 -0.99 6.6e-06 APEH LONRF2 MST1R RBM6 RNF123 THEM6 UBA7
Relative age voice broke 2.07 2 0 0.0 0.00 1.0e+00 NRBF2 POM121C
Taking other prescription medications 5.07 4 4 8.9 -1.00 1.4e-05 MST1R RBM6 RNF123 UBA7
Age when periods started (menarche) 3.90 7 3 6.7 -0.74 5.6e-02 APEH MED8 MST1R NEGR1 NRBF2 RBM6 ST3GAL3
Heel bone mineral density (BMD) T-score, automated (left) 2.58 4 2 4.4 -0.99 7.1e-04 MST1R RBM6 RNF123 UBA7
Qualifications: CSEs or equivalent 4.41 6 0 0.0 -0.98 7.3e-04 FOXO6 MST1R RBM6 RNF123 ST3GAL3 UBA7
High blood pressure 1.96 4 0 0.0 -0.11 8.9e-01 MED8 NEGR1 NRBF2 TSNARE1
Hayfever, allergic rhinitis or eczema 1.82 3 0 0.0 0.00 1.0e+00 IP6K2 NEGR1 RP11-282O18.3
Sitting height 1.47 4 2 4.4 0.93 6.9e-02 CAMKMT MED8 RP11-282O18.3 ST3GAL3
Body mass index (BMI) 8.63 15 9 20.0 -0.89 4.2e-06 APEH CADM2 CAMKMT IP6K2 LIN37 LONRF2 MPP6 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 THEM6 UBA7
Impedance of leg (left) 2.37 10 5 11.1 0.38 2.6e-01 AP001877.1 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Leg predicted mass (left) 3.34 11 8 17.8 -0.53 7.6e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Trunk fat mass 5.57 11 8 17.8 -0.88 1.6e-04 APEH CADM2 IP6K2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Waist circumference 5.78 10 8 17.8 -0.85 9.8e-04 APEH CADM2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Past tobacco smoking 3.01 3 1 2.2 0.00 1.0e+00 CADM2 CELF2 TANK
Alcohol usually taken with meals 5.75 7 1 2.2 1.00 6.1e-07 CADM2 ERCC8 GRIN2A MED8 NEGR1 NRBF2 TSNARE1
Nervous feelings 1.77 3 1 2.2 0.00 1.0e+00 AP001877.1 CADM2 TSNARE1
Forced vital capacity (FVC) 1.60 5 0 0.0 0.75 1.5e-01 APEH FAM160A1 FOXO6 MST1R UBA7
Heel bone mineral density (BMD) T-score, automated (right) 2.34 4 1 2.2 -0.99 9.3e-04 MST1R RBM6 RNF123 UBA7
Qualifications: None of the above 14.53 24 18 40.0 -0.98 1.3e-17 AP001877.1 APEH ARTN CAMKMT CELF2 CKM ERCC8 FAM160A1 GRIN2A LONRF2 MED8 MPP6 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK THEM6 TSNARE1 UBA7
Allergy 1.69 2 1 2.2 0.00 1.0e+00 NEGR1 RP11-282O18.3
Diabetes (self-reported) 3.84 3 2 4.4 -1.00 3.9e-03 RBM6 RNF123 UBA7
Fluid intelligence score 11.22 17 9 20.0 0.99 1.7e-14 APEH ARTN CAMKMT CELF2 CKM FAM160A1 FOXO6 LONRF2 MED8 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK UBA7
Illnesses of siblings 2.44 1 0 0.0 0.00 1.0e+00 ST3GAL3
Neuroticism score 2.28 3 0 0.0 0.00 1.0e+00 CELF2 RNF123 UBA7
Weight 5.69 11 8 17.8 -0.76 4.4e-03 APEH CADM2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 THEM6 UBA7
Impedance of arm (right) 4.49 9 7 15.6 0.80 5.9e-03 APEH CADM2 ERCC8 MST1R NEGR1 NRBF2 RBM6 RNF123 UBA7
Arm fat percentage (right) 6.19 13 8 17.8 -0.88 2.8e-05 APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Trunk fat-free mass 2.46 9 7 15.6 -0.40 2.5e-01 CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Hip circumference 4.11 11 8 17.8 -0.68 1.6e-02 APEH CADM2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 THEM6 UBA7
Alcohol intake versus 10 years previously 6.71 6 4 8.9 -0.87 1.0e-02 APEH MST1R NEGR1 RBM6 RNF123 UBA7
Father's age at death 3.39 3 0 0.0 0.00 1.0e+00 APEH RNF123 UBA7
Worrier / anxious feelings 2.29 2 1 2.2 0.00 1.0e+00 AP001877.1 CADM2
Number of live births 2.84 2 0 0.0 0.00 1.0e+00 RBM6 RNF123
Forced expiratory volume in 1-second (FEV1) 1.83 4 0 0.0 0.99 1.4e-02 APEH GPD2 MST1R UBA7
Pulse rate 1.35 1 0 0.0 0.00 1.0e+00 IP6K2
Noisy workplace 3.43 1 0 0.0 0.00 1.0e+00 LIN37
Mouth/teeth dental problems: Dentures 4.43 4 0 0.0 -1.00 2.2e-04 MST1R RBM6 RNF123 UBA7
Prospective memory result 3.28 1 0 0.0 0.00 1.0e+00 RBM6
Forced expiratory volume in 1-second (FEV1), Best measure 2.00 4 0 0.0 1.00 3.3e-03 APEH MST1R RNF123 UBA7
Impedance of arm (left) 4.43 10 7 15.6 0.82 2.0e-03 APEH CADM2 ERCC8 LIN37 MST1R NEGR1 NRBF2 RBM6 RNF123 UBA7
Arm fat mass (right) 7.20 11 8 17.8 -0.88 1.9e-04 APEH CADM2 IP6K2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Trunk predicted mass 2.43 9 6 13.3 -0.39 2.6e-01 CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Standing height 1.20 6 3 6.7 0.97 1.6e-03 CAMKMT FAM160A1 MED8 MPP6 NRBF2 RP11-282O18.3
Exposure to tobacco smoke at home 3.84 2 0 0.0 0.00 1.0e+00 RNF123 UBA7
Breastfed as a baby 2.95 1 0 0.0 0.00 1.0e+00 RP11-282O18.3
Seen doctor (GP) for nerves, anxiety, tension or depression 2.51 1 1 2.2 0.00 1.0e+00 NEGR1
Ever highly irritable/argumentative for 2 days 3.99 4 0 0.0 -1.00 2.2e-04 MST1R RBM6 RNF123 UBA7
Qualifications: O levels/GCSEs or equivalent 9.30 16 3 6.7 0.96 2.2e-09 AP001877.1 APEH ARTN CAMKMT CKM FAM160A1 GPD2 MPP6 MST1R NRBF2 POM121C RNF123 RP11-282O18.3 ST3GAL3 THEM6 TSNARE1
Medication for cholesterol, blood pressure or diabetes 3.56 3 0 0.0 0.00 1.0e+00 RBM6 RNF123 UBA7
Hypothyroidism/myxoedema (self-reported) 1.15 1 0 0.0 0.00 1.0e+00 TANK
Medication: Ventolin 100micrograms inhaler 2.41 2 0 0.0 0.00 1.0e+00 RBM6 UBA7
Chronic bronchitis/emphysema (mother) 3.25 2 0 0.0 0.00 1.0e+00 RBM6 UBA7
Forced vital capacity (FVC), Best measure 1.84 5 0 0.0 0.82 9.0e-02 APEH FOXO6 MST1R RNF123 UBA7
Body fat percentage 6.43 13 10 22.2 -0.89 2.0e-05 APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Leg fat percentage (right) 8.44 14 10 22.2 -0.89 6.8e-06 AP001877.1 APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm fat-free mass (right) 3.82 10 7 15.6 -0.55 7.9e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Exposure to tobacco smoke outside home 3.36 1 0 0.0 0.00 1.0e+00 UBA7
Comparative body size at age 10 2.81 3 2 4.4 0.00 1.0e+00 CADM2 ERCC8 NEGR1
Worry too long after embarrassment 1.64 1 0 0.0 0.00 1.0e+00 THEM6
Wheeze or whistling in the chest in last year 5.25 5 4 8.9 -0.99 1.1e-04 APEH MST1R RBM6 RNF123 UBA7
Number of children fathered 2.36 1 0 0.0 0.00 1.0e+00 CADM2
Age at first live birth 9.04 7 4 8.9 0.99 6.5e-07 AP001877.1 APEH MST1R NRBF2 RBM6 RNF123 UBA7
Health satisfaction 3.01 2 0 0.0 0.00 1.0e+00 TSNARE1 UBA7
Qualifications: College or University degree 18.88 31 20 44.4 0.98 2.1e-24 AP001877.1 APEH ARTN CADM2 CAMKMT CELF2 CKM CUEDC2 ERCC8 FAM160A1 FOXO6 GPD2 GRIN2A IP6K2 LIN37 LONRF2 MAD1L1 MED8 MPP6 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK THEM6 TSNARE1 UBA7
Medication for pain relief, constipation, heartburn 2.58 1 0 0.0 0.00 1.0e+00 RP11-282O18.3
Medication: Blood pressure 2.51 1 0 0.0 0.00 1.0e+00 RNF123
Medication: Seretide 50 evohaler 2.85 1 0 0.0 0.00 1.0e+00 UBA7
Mean time to correctly identify matches 2.38 1 0 0.0 0.00 1.0e+00 RNF123
Whole body fat mass 6.91 12 9 20.0 -0.88 6.3e-05 APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Leg fat mass (right) 8.47 12 9 20.0 -0.88 6.3e-05 APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm predicted mass (right) 3.87 10 7 15.6 -0.56 7.0e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Pulse rate, automated reading 3.18 8 5 11.1 -0.85 3.9e-03 APEH IP6K2 MST1R NEGR1 POM121C RBM6 RNF123 UBA7
Alcohol intake frequency. 4.73 8 4 8.9 -0.90 9.7e-04 APEH MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 TSNARE1 UBA7
Comparative height size at age 10 1.72 5 3 6.7 0.99 1.3e-03 CAMKMT FAM160A1 MED8 RP11-282O18.3 ST3GAL3
Overall health rating 7.37 9 6 13.3 -0.99 7.2e-08 APEH CKM MST1R RBM6 RNF123 TANK THEM6 TSNARE1 UBA7
Age at last live birth 8.58 7 4 8.9 0.99 1.1e-06 AP001877.1 APEH LONRF2 MST1R RBM6 RNF123 UBA7
Leg pain on walking 4.72 4 3 6.7 -1.00 4.8e-05 MST1R RBM6 RNF123 UBA7
Qualifications: NVQ or HND or HNC or equivalent 4.30 3 0 0.0 -1.00 2.5e-03 MST1R RBM6 RNF123
Commuting to job workplace: Car/motor vehicle 2.67 1 0 0.0 0.00 1.0e+00 NEGR1
Knee pain experienced in last month 2.83 1 0 0.0 0.00 1.0e+00 RBM6
Hypertension (Self-reported) 1.92 5 0 0.0 -0.64 2.5e-01 MPP6 NEGR1 NRBF2 THEM6 TSNARE1
Smoking status: Previous 2.56 1 1 2.2 0.00 1.0e+00 CADM2
Whole body fat-free mass 2.94 9 8 17.8 -0.46 1.8e-01 CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Leg fat-free mass (right) 2.97 10 8 17.8 -0.49 1.3e-01 CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Arm fat percentage (left) 6.25 13 8 17.8 -0.88 3.3e-05 APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Average weekly red wine intake 5.44 4 1 2.2 0.98 1.8e-02 AP001877.1 CAMKMT NRBF2 RP11-282O18.3
Mood swings 4.47 6 2 4.4 -0.99 4.7e-05 APEH CELF2 MST1R RBM6 RNF123 UBA7
Loneliness, isolation 2.71 1 0 0.0 0.00 1.0e+00 APEH
Long-standing illness, disability or infirmity 2.07 1 0 0.0 0.00 1.0e+00 NEGR1
Ever had bowel cancer screening 2.74 2 0 0.0 0.00 1.0e+00 RNF123 UBA7
Diabetes diagnosed by doctor 3.30 3 1 2.2 -0.99 7.9e-03 RBM6 RNF123 UBA7
Friendships satisfaction 2.13 1 0 0.0 0.00 1.0e+00 AP001877.1
Qualifications: nursing, teaching 9.33 14 6 13.3 0.96 2.6e-08 AP001877.1 APEH CADM2 CELF2 ERCC8 FAM160A1 MAD1L1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 ST3GAL3 UBA7
Mouth/teeth dental problems: Mouth ulcers 1.74 1 0 0.0 0.00 1.0e+00 AP001877.1
Osteoporosis (self-reported) 1.49 1 0 0.0 0.00 1.0e+00 IP6K2
Illnesses of father: None of the above (group 1) 1.53 1 0 0.0 0.00 1.0e+00 CUEDC2
Smoking status: Current 3.26 1 1 2.2 0.00 1.0e+00 ST3GAL3
Whole body water mass 3.02 10 8 17.8 -0.47 1.4e-01 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Leg predicted mass (right) 2.96 10 7 15.6 -0.48 1.3e-01 CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Arm fat mass (left) 7.12 11 8 17.8 -0.87 2.0e-04 APEH CADM2 IP6K2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Number of self-reported non-cancer illnesses 2.18 1 1 2.2 0.00 1.0e+00 NEGR1
Miserableness 5.00 7 4 8.9 -0.99 2.9e-06 APEH CELF2 MST1R RBM6 RNF123 TANK UBA7
Financial situation satisfaction 3.81 3 0 0.0 0.00 1.0e+00 APEH RNF123 UBA7
Commuting to job workplace: Public transport 3.77 2 0 0.0 0.00 1.0e+00 LONRF2 NEGR1
High cholesterol (Self-reported) 1.05 1 0 0.0 0.00 1.0e+00 CADM2
Ever smoked 2.59 2 1 2.2 0.00 1.0e+00 CADM2 CELF2
Basal metabolic rate 3.59 10 8 17.8 -0.55 8.1e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Leg fat percentage (left) 8.47 13 11 24.4 -0.90 1.5e-05 APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm fat-free mass (left) 4.12 10 7 15.6 -0.58 6.3e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Number of operations (self-reported) 2.79 2 0 0.0 0.00 1.0e+00 NEGR1 TANK
Average weekly beer plus cider intake 5.67 6 1 2.2 -0.98 6.4e-05 CADM2 MST1R NRBF2 RBM6 RNF123 UBA7
Irritability 1.21 1 0 0.0 0.00 1.0e+00 CELF2
Risk taking 3.13 3 1 2.2 0.00 1.0e+00 CADM2 FAM160A1 GRIN2A
Fractured/broken bones in last 5 years 1.96 1 0 0.0 0.00 1.0e+00 ERCC8
Age started oral contraceptive pill 3.16 1 0 0.0 0.00 1.0e+00 RNF123
Diastolic blood pressure, automated reading 5.10 12 8 17.8 -0.89 5.7e-05 APEH MED8 MPP6 MST1R NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 THEM6 TSNARE1 UBA7
Unable to work because of sickness or disability 2.24 1 0 0.0 0.00 1.0e+00 ERCC8
Vascular/heart problems diagnosed by doctor 2.21 4 0 0.0 0.40 6.0e-01 MED8 NEGR1 NRBF2 TSNARE1
Pain experienced in last month 3.89 5 0 0.0 1.00 2.2e-06 APEH MST1R RBM6 RNF123 UBA7
Alcohol drinker status: Previous 1.74 1 0 0.0 0.00 1.0e+00 POM121C
Impedance of whole body 3.57 11 9 20.0 0.78 2.7e-03 APEH CADM2 ERCC8 LIN37 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 UBA7
Leg fat mass (left) 8.56 12 9 20.0 -0.88 6.5e-05 APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm predicted mass (left) 4.18 10 7 15.6 -0.58 6.1e-02 APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 9 0.258 2.3
GTEx Adipose Visceral Omentum 9 0.442 2.4
GTEx Adrenal Gland 1 0.069 2.1
GTEx Artery Aorta 10 0.336 2.3
GTEx Artery Coronary 2 0.169 2.2
GTEx Artery Tibial 13 0.346 2.3
GTEx Brain Caudate basal ganglia 3 0.326 2.4
GTEx Brain Cerebellar Hemisphere 8 0.537 2.6
GTEx Brain Cerebellum 7 0.353 2.4
GTEx Brain Cortex 3 0.290 2.3
GTEx Brain Frontal Cortex BA9 5 0.541 2.5
GTEx Brain Hippocampus 1 0.191 2.0
GTEx Brain Hypothalamus 2 0.339 2.4
GTEx Brain Nucleus accumbens basal ganglia 1 0.116 2.3
GTEx Brain Putamen basal ganglia 2 0.321 2.4
GTEx Breast Mammary Tissue 5 0.253 2.4
GTEx Breast Mammary Tissue (Male) 1 0.084 2.2
GTEx Breast Mammary Tissue (Female) 5 0.304 2.3
GTEx Cells EBV-transformed lymphocytes 3 0.211 2.4
GTEx Cells Transformed fibroblasts 19 0.452 2.3
GTEx Colon Sigmoid 6 0.410 2.4
GTEx Colon Transverse 7 0.339 2.4
GTEx Esophagus Gastroesophageal Junction 6 0.415 2.5
GTEx Esophagus Mucosa 12 0.361 2.4
GTEx Esophagus Muscularis 13 0.402 2.4
GTEx Heart Atrial Appendage 3 0.190 2.5
GTEx Heart Left Ventricle 5 0.327 2.4
GTEx Liver 4 0.558 2.3
GTEx Lung 10 0.348 2.3
GTEx Muscle Skeletal 10 0.346 2.4
GTEx Nerve Tibial 19 0.440 2.3
GTEx Ovary 1 0.110 2.4
GTEx Pancreas 9 0.551 2.5
GTEx Pituitary 3 0.269 2.2
GTEx Prostate 1 0.120 2.3
GTEx Skin Not Sun Exposed Suprapubic 10 0.407 2.4
GTEx Skin Sun Exposed Lower leg 14 0.385 2.3
GTEx Small Intestine Terminal Ileum 3 0.651 2.4
GTEx Spleen 3 0.213 2.4
GTEx Stomach 4 0.275 2.4
GTEx Testis 8 0.254 2.2
GTEx Thyroid 14 0.350 2.3
GTEx Uterus 0 0.000 2.4
GTEx Vagina 1 0.157 2.6
GTEx Whole Blood 4 0.201 2.2
METSIM Adipose 11 0.239 2.1
NTR Blood 9 0.375 2.1
ROSMAP Brain Pre-frontal Cortex 11 0.251 2.3
YFS Blood 9 0.195 2.0
CommonMind Brain Pre-frontal Cortex 10 0.186 2.1
The Cancer Genome Atlas Bladder Urothelial Carcinoma 4 0.242 2.2
The Cancer Genome Atlas Breast Invasive Carcinoma 10 0.227 2.1
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.273 2.2
The Cancer Genome Atlas Colon Adenocarcinoma 3 0.145 2.1
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 2.0
The Cancer Genome Atlas Glioblastoma Multiforme 4 0.391 2.3
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 7 0.257 2.1
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 11 0.268 2.1
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 9 0.439 2.2
The Cancer Genome Atlas Brain Lower Grade Glioma 13 0.302 2.1
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 3 0.271 2.3
The Cancer Genome Atlas Lung Adenocarcinoma 8 0.272 2.1
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 6 0.239 2.2
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 3 0.188 2.1
The Cancer Genome Atlas Pancreatic Adenocarcinoma 8 0.482 2.2
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 5 0.377 2.2
The Cancer Genome Atlas Prostate Adenocarcinoma 11 0.238 2.0
The Cancer Genome Atlas Rectum Adenocarcinoma 1 0.145 2.1
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 2.3
The Cancer Genome Atlas Stomach Adenocarcinoma 3 0.178 2.1
The Cancer Genome Atlas Testicular Germ Cell Tumors 3 0.235 2.2
The Cancer Genome Atlas Thyroid Carcinoma 16 0.310 2.0
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 2.1